Human chorionic gonadotropin levels after blastocyst transfer are highly predictive of pregnancy outcome.
T C Papageorgiou, M P Leondires, B T Miller...
https://pubmed.ncbi.nlm.nih.gov/11704121/Actively Recruiting
Led by BetaPlus Center for Reproductive Medicine · Updated on 2026-10-07
2200
Participants Needed
2
Research Sites
39 weeks
Total Duration
Researchers are evaluating a machine-learning model to predict pregnancy outcomes in women who have a positive pregnancy test after assisted reproductive treatments ART, mainly focusing on in vitro fertilization IVF and frozen embryo transfer FET. The study also explores pregnancies following intrauterine insemination IUI. The goal is to determine if early blood levels of beta-human chorionic gonadotropin beta-hCG can predict live birth likelihood and identify pregnancies at risk of early loss. Participants include women who underwent ART procedures and have at least one early positive serum beta-hCG measurement. The study collects clinical and treatment data from medical records or prospective follow-up but does not change any medical treatment. Data from retrospective and prospective patients will be used to develop and validate the AI-based prognostic model. Participants will have their clinical information, beta-hCG measurements, and pregnancy outcomes collected through direct patient reports or clinic follow-up calls. The main outcome measured is live birth following ART, with secondary outcomes including biochemical pregnancy and early pregnancy loss up to 12 weeks gestation. The study runs from January 2026 to September 2027 and involves no interventions or treatment changes.
CONDITIONS
Machine-Learning Prediction of Pregnancy Outcomes After Assisted Reproductive Treatments
R
Romana Dmitrovic
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
BetaPlus Center for Reproductive Medicine
Lead Sponsor
Clinical Hospital Center Rijeka
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 21 months
Participants' clinical information, beta-hCG levels, and pregnancy outcomes are collected from medical records and through follow-up contacts without changing any medical treatment.
Periodic follow-up contacts
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
T C Papageorgiou, M P Leondires, B T Miller...
https://pubmed.ncbi.nlm.nih.gov/11704121/Lydia M Hughes, Adrienne Schuler, Maxwell Sharmuk...
https://pubmed.ncbi.nlm.nih.gov/36074224/Naama Al Mamari, Nabighah Al Zawawi, Suhaib Khayat...
https://pubmed.ncbi.nlm.nih.gov/31605261/Elie Hobeika, Sonali Singh, Shaveta Malik...
https://pubmed.ncbi.nlm.nih.gov/28639180/L L Schmidt, R H Asch, J L Frederick...
https://pubmed.ncbi.nlm.nih.gov/8034081/Gonul Ozer
https://pubmed.ncbi.nlm.nih.gov/37861533/Galia Oron, Tal Shavit, Efrat Esh-Broder...
https://pubmed.ncbi.nlm.nih.gov/28625759/Ali Mourad, Roland Antaki, Mélanie Rowen...
https://pubmed.ncbi.nlm.nih.gov/38043845/Nobuyuki Kidera, Tomonori Ishikawa, Toshihiro Kawamura...
https://pubmed.ncbi.nlm.nih.gov/41473560/Emily A Clarke, Charlotte Jones, Jensen Reckhow...
https://pubmed.ncbi.nlm.nih.gov/42092529/BetaPlus Center for Reproductive Medicine
Lead Sponsor
Clinical Hospital Center Rijeka
Collaborating Sponsor